Showing 4751-4760 of 8095 results for "".
- Dermatologists React to Threat of Coronavirus Pandemichttps://practicaldermatology.com/news/dermatologists-react-to-threat-of-coronavirus-pandemic/2460291/Reports about COVID-19 are causing many dermatologists to rethink their travel plans and update their office policy on the care of sick patients. The International Health Regulations Emergency Committee of the World Health Organization declared the outbreak a “public health emerge
- Acne Pipeline Watch: Dermata Therapeutics Completes Enrollment in Phase 2b Trial of Once-Weekly Topical DMT310 for Acnehttps://practicaldermatology.com/news/acne-pipeline-watch-dermata-therapeutics-completes-enrollment-in-phase-2b-trial-of-once-weekly-topical-dmt310-for-acne/2460282/Dermata Therapeutics, LLC completed enrollment of patients in its Phase 2b clinical trial evaluating the safety, tolerability and efficacy of DMT310 in moderate to severe acne patients. The Phase 2b trial enrolled 182 patients randomly in two group
- Aerolase and Eucerin Join Forces to Optimize Patient Outcomes in Laser Treatmentshttps://practicaldermatology.com/news/aerolase-and-eucerin-join-forces-to-optimize-patient-outcomes-in-laser-treatments-1/2460277/Aerolase and Eucerin are working together to optimize laser treatment protocols in the D-A-CH-region (Germany-Austria-Switzerland). Furthermore, both companies will develop therapies for adjunctive care post-laser treatments. Both companies will also conduct a joint symposium
- Cold Plasma Patch May Make Immunotherapy More Effective for Treating Melanomahttps://practicaldermatology.com/news/cold-plasma-patch-may-make-immunotherapy-more-effective-for-treating-melanoma/2460275/A new medicated patch that can deliver immune checkpoint inhibitors and cold plasma directly to tumors may help boost the immune response and kill cancer cells, according to an interdisciplinary team of researchers at the UCLA Jonsson Comprehensive Cancer Center. The thumb-sized patch h
- Neuromodulators and Fillers Top RealSelf's List of Most Worth It Procedures of 2020https://practicaldermatology.com/news/neuromodulators-and-fillers-top-realselfs-list-of-most-worth-it-procedures-of-2020-1/2460272/A total of 15 nonsurgical and 37 surgical procedures earned Real Self’s Most Worth It designation for 2020. The RealSelf Worth It Rating is a proprietary consumer satisfaction score based on reviews from consumers on RealSelf who, after undergoing a treatment, rated it as "Wo
- Derms Still Need Disaster Preparedness Traininghttps://practicaldermatology.com/news/derms-still-need-disaster-preparedness-training/2460271/The dermatology community is inadequately prepared for a biological disaster and would benefit from a formal preparedness training program, according to a study from the George Washington University (GW) that appears in the Jour
- Dermal Fillers Restore Youthful Facial Movement Toohttps://practicaldermatology.com/news/dermal-fillers-restore-youthful-facial-movement-too-1/2460269/Dermal fillers do more than just fill in wrinkles, they also restore a more youthful pattern of facial movement and expressiveness, according to a
- BioPharmX Corporation and Timber Pharmaceuticals LLC Announce Mergerhttps://practicaldermatology.com/news/biopharmx-corporation-and-timber-pharmaceuticals-llc-announce-merger/2460267/BioPharmX Corporation and Timber Pharmaceuticals LLC have entered into a definitive merger agreement. Under the terms of the merger agreement, subject to the approval of BioPharmX's stockholders and Timber's members, a wholly-owned subsidiary of BioPharmX will be merged wit
- Cynosure Taps Todd Tillemans As New CEOhttps://practicaldermatology.com/news/cynosure-taps-todd-tillemans-as-new-ceo-2/2460262/Todd Tillemans is the new Chief Executive Officer of Cynosure, LLC. Mr. Tillemans is the former President of Hershey's flagship U.S. business generating more than $6.5 billion in annual sales. Prior to that, he held various leadership positions across Unilever's
- Revance Acquires Exclusive US Distribution Rights to Teoxane SA Fillershttps://practicaldermatology.com/news/revance-acquires-exclusive-us-distribution-rights-to-teoxane-sa-fillers-1/2460250/Revance Therapeutics, Inc. is the exclusive commercialization partner of Teoxane SA in the US. With a new distribution agreement just announced, Revance gains immediate and exclusive rights to commercialize Teoxane’s Resilient Hyaluronic Acid® (RHA®) line of fillers in the